1.Determination of Inorganic Mercury and Total Organomercury in ChemicalWaste Water by Cold Vapor Generation-Atomic Fluorescence Spectrometry
Lina LIANG ; Guibin JIANG ; Jingtian HU
Chinese Journal of Analytical Chemistry 2001;49(4):403-405
A sensitive method for the determination of inorganic mercury and total organomercury in chemical waste water by cold vapor generation-atomic fluorescence spectrometry (CVG-AFS) was proposed. Inorganic mercury was directly determined by CVG-AFS. Organomercury was oxidized by potassium persulfate to its inorganic form prior to analysis. The difference between the two data was the value of total organomercury. Parameters affecting the sensitity in the process for the determination of mercury had been studied and optimized. Detection limit of mercury chloride was 8.2 ng/L.
2.Expression and methylation status of IGFBP-rP1 gene in laryngocarcinoma.
Junlan HU ; Ruili ZHAO ; Ganxun WU ; Jingtian WANG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2013;27(24):1352-1359
OBJECTIVE:
To investigate the relationship between the promoter methylation and protein expression of insulin-like growth factor binding protein-related protein 1(IGFBP-rP1) in laryngeal squamous cell carcinoma (LSCC).
METHOD:
Methylation specific PCR (MSP) approach and immunohistochemistry methods were used to examine the methylation status and protein expression of IGFBP-rP1 in 45 samples of laryngeal carcinoma and 18 samples of tissues beside cancer.
RESULT:
For the promoter site, methylation frequency of IGFBP-rP1 in tumor specimens (33.3%, 15/45) was significantly higher than that in corresponding normal tissues (5.6%, 1/18) (P < 0.05). The protein expression of IGFBP-rP1 in tumor tissues was significantly higher than that in corresponding normal tissues (P < 0.05) and was inversely correlated with its methylation status of promoter.
CONCLUSION
Epigenetic silencing of IGFBP-rP1 gene expression by promoter hypermethylation may play an important role in LSCC.
Adenocarcinoma
;
genetics
;
metabolism
;
pathology
;
Aged
;
DNA Methylation
;
Female
;
Humans
;
Insulin-Like Growth Factor Binding Proteins
;
genetics
;
metabolism
;
Laryngeal Neoplasms
;
genetics
;
metabolism
;
pathology
;
Male
;
Middle Aged
3.Selection and application of ear reconstruction surgery for Chinese microtia.
Zhou XU ; Wang YUE ; Zhang QINGGUO ; Liu TUN ; Xie YANGCHUN ; Hu JINGTIAN ; Qian JIN ; Wang BINGQING ; Cheng LIN
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2015;50(3):192-196
OBJECTIVEBased on the different physiological characteristics of the mastoid skin and soft tissue of Chinese congenital microtia malformation, the Nagata two-stage method was respectively applied for ear reconstruction, and the clinic experience were investigated in this study.
METHODAccording to the mastoid skin and soft tissue difference in the thickness and tightness, 280 patients diagnosed with congenital microtia were divided into four types: thin and tight, thin and loose, thick and tight, thick and loose type. 90 cases of thin and loose type accepted the Nagata method of ear reconstruction surgery.
RESULTSWith average 7.8 months follow up, 84.4% (76/90) cases using Nagata two-stage method were satisfied with the outcome of the reconstructed ear including three dimensional position and subunit appearance. There were no postoperative complication related to chest wall deformity or affected normal physical function.
CONCLUSIONSThe Nagata two-stage method is appropriate management choice for Chinese congenital microtia. Based on the different physiological characteristics of the mastoid skin and soft tissue, the selection of different operational should be beneficial to the ear reconstruction of Chinese congenital microtia malformation.
China ; Congenital Microtia ; surgery ; Ear, External ; surgery ; Humans ; Mastoid ; Otologic Surgical Procedures ; Reconstructive Surgical Procedures ; Skin ; Thoracic Wall
4.Advances in the Adjunctive Treatment of Lennox-Gastaut Syndrome with Clobazam and Cannabidiol
Jingtian SHI ; Chaoyang CHEN ; Ting YANG ; Ran WEI ; Xuanling ZHANG ; Zining WANG ; Xiaojuan HU ; Ying ZHOU
JOURNAL OF RARE DISEASES 2024;3(2):252-259
Lennox-Gastaut syndrome (LGS) is a severe, epileptic encephalopathy.In recent years, a variety of drugs have been approved for the treatment of LGS. The U.S. Food and Drug Administration approved clobazam and cannabidiol as adjunctive therapy for LGS in October 2011 and June 2018, respectively. This article provides an overview of clobazam and cannabidiol, including their chemical structures, pharmacological actions, curative effects, safety profile, drug interactions, to introduce the current state of research and the achievements of both drugs.